From germline towards somatic mutations in the pathophysiology of vascular anomalies

Human Molecular Genetics

Volumn 18, Issue R1, 2009, Pages

  Limaye, Nisha ^a   Boon, Laurence M ^a,b   Vikkula, Miikka ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BRAIN PROTEIN; CEREBRAL CAVERNOUS MALFORMATION PROTEIN; FIBRONECTIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTEGRIN; PROTEIN RASA1; PROTEIN TEK; TIE 1 RECEPTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SOX18; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANGIOMA SERPIGINOSUM; ARTERIOVENOUS MALFORMATION; AUTOSOMAL DOMINANT INHERITANCE; BRAIN MALFORMATION; CAPILLARY PROLIFERATION; CEREBRAL CAVERNOUS MALFORMATION; CONGENITAL BLOOD VESSEL MALFORMATION; CUTANEOMUCOSAL VENOUS MALFORMATION; FAMILIAL DISEASE; GENE FUNCTION; GENE MUTATION; GERM LINE; HUMAN; HYPOTRICHOSIS LYMPHEDEMA TELANGIECTASIA; LYMPHANGIOGENESIS; LYMPHATIC MALFORMATION; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SKIN DISEASE; SOMATIC MUTATION; TUMOR VASCULARIZATION; VEIN MALFORMATION;

HUMANS; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR DISEASES; VASCULAR MALFORMATIONS;

ANIMALIA;

EID: 63149086659     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp002     Document Type: Review

References (117)

1. Mulliken, J.B. and Glowacki, J. (1982) Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast. Reconstr. Surg., 69, 412-422.
2. Jinnin, M., Medici, D., Park, L., Limaye, N., Liu, Y., Boscolo, E., Bischoff, J., Vikkula, M., Boye, E. and Olsen, B.R. (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat. Med., 14, 1236-1246.
3. Khan, Z.A., Boscolo, E., Picard, A., Psutka, S., Melero-Martin, J.M., Bartch, T.C., Mulliken, J.B. and Bischoff, J. (2008) Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J. Clin. Invest., 118, 2592-2599.
4. Boon, L.M. and Vikkula, M. (2007) Vascular malformations. Fitzpatrick's Dermatology in General Medicine, 7th edn. McGraw-Hill Professional Publishing, Maidenhead.
5. Mulliken, J.B. and Young, A.E. (1988) Vascular Birthmarks: Hemangiomas and Malformations, WB Saunders, Philadelphia.
6. Brouillard, P. and Vikkula, M. (2007) Genetic causes of vascular malformations. Hum. Mol. Genet., 16 Spec No. 2, R140-149.
7. Boon, L.M., Mulliken, J.B. and Vikkula, M. (2005) RASA1: Variable phenotype with capillary and arteriovenous malformations. Curr. Opin. Genet. Dev., 15, 265-269.
8. Revencu, N., Boon, L.M., Mulliken, J.B., Enjolras, O., Cordisco, M.R., Burrows, P.E., Clapuyt, P., Hammer, F., Dubois, J., Baselga, E. et al. (2008) Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum. Mutat., 29, 959-965.
9. Eerola, I., Boon, L.M., Mulliken, J.B., Burrows, P.E., Dompmartin, A., Watanabe, S., Vanwijck, R. and Vikkula, M. (2003) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet., 73, 1240-1249.
10. Boon, L.M., Mulliken, J.B., Vikkula, M., Watkins, H., Seidman, J., Olsen, B.R. and Warman, M.L. (1994) Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Hum. Mol. Genet., 3, 1583-1587.
11. Henkemeyer, M., Rossi, D.J., Holmyard, D.P., Puri, M.C., Mbamalu, G., Harpal, K., Shih, T.S., Jacks, T. and Pawson, T. (1995) Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature, 377, 695-701.
12. Vikkula, M. (2007) Vascular pathologies. Angiogenomics: Towards a genetic nosology and understanding of vascular anomalies. Eur. J. Hum. Genet., 15, 821-822.
13. Blinkenberg, E.O., Brendehaug, A., Sandvik, A.K., Vatne, O., Hennekam, R.C. and Houge, G. (2007) Angioma serpiginosum with oesophageal papillomatosis is an X-linked dominant condition that maps to Xp11.3-Xq12. Eur. J. Hum. Genet., 15, 543-547.
14. Houge, G., Oeffner, F. and Grzeschik, K.H. (2008) An Xp11.23 deletion containing PORCN may also cause angioma serpiginosum, a cosmetic skin disease associated with extreme skewing of X-inactivation. Eur. J. Hum. Genet., 16, 1027-1028.
15. Grzeschik, K.H., Bornholdt, D., Oeffner, F., Konig, A., del Carmen Boente, M., Enders, H., Fritz, B., Hertl, M., Grasshoff, U., Hofling, K. et al. (2007) Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat. Genet., 39, 833-835.
16. Wang, X., Reid Sutton, V., Omar Peraza-Llanes, J., Yu, Z., Rosetta, R., Kou, Y.C., Eble, T.N., Patel, A., Thaller, C., Fang, P. et al. (2007) Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. Nat. Genet., 39, 836-838.
17. Wong, J.H., Awad, I.A. and Kim, J.H. (2000) Ultrastructural pathological features of cerebrovascular malformations: A preliminary report. Neurosurgery, 46, 1454-1459.
18. Clatterbuck, R.E., Eberhart, C.G., Crain, B.J. and Rigamonti, D. (2001) Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J. Neurol. Neurosurg. Psychiatry, 71, 188-192.
19. Labauge, P., Enjolras, O., Bonerandi, J.J., Laberge, S., Dandurand, M., Joujoux, J.M. and Tournier-Lasserve, E. (1999) An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. Ann. Neurol., 45 250-254.
20. Eerola, I., Plate, K.H., Spiegel, R., Boon, L.M., Mulliken, J.B. and Vikkula, M. (2000) KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum. Mol. Genet., 9, 1351-1355.
21. Revencu, N. and Vikkula, M. (2006) Cerebral cavernous malformation: New molecular and clinical insights. J. Med. Genet., 43, 716-721.
22. Laberge-le Couteulx, S., Jung, H.H., Labauge, P., Houtteville, J.P., Lescoat, C., Cecillon, M., Marechal, E., Joutel, A., Bach, J.F. and Tournier-Lasserve, E. (1999) Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet., 23, 189-193.
23. Sahoo, T., Johnson, E.W., Thomas, J.W., Kuehl, P.M., Jones, T.L., Dokken, C.G., Touchman, J.W., Gallione, C.J., Lee-Lin, S.Q., Kosofsky, B. et al. (1999) Mutations in the gene encoding KRIT1, a Krev-1/ rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum. Mol. Genet., 8, 2325-2333.
24. Liquori, C.L., Berg, M.J., Siegel, A.M., Huang, E., Zawistowski, J.S., Stoffer, T., Verlaan, D., Balogun, F., Hughes, L., Leedom, T.P. et al. (2003) Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am. J. Hum. Genet., 73, 1459-1464.
25. Bergametti, F., Denier, C., Labauge, P., Arnoult, M., Boetto, S., Clanet, M., Coubes, P., Echenne, B., Ibrahim, R., Irthum, B. et al. (2005) Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am. J. Hum. Genet., 76, 42-51.
26. Liquori, C.L., Berg, M.J., Squitieri, F., Ottenbacher, M., Sorlie, M., Leedom, T.P., Cannella, M., Maglione, V., Ptacek, L., Johnson, E.W. et al. (2006) Low frequency of PDCD10 mutations in a panel of CCM3 probands: Potential for a fourth CCM locus. Hum. Mutat., 27, 118.
27. Verlaan, D.J., Laurent, S.B., Rouleau, G.A. and Siegel, A.M. (2004) No CCM2 mutations in a cohort of 31 sporadic cases. Neurology, 63 1979.
28. Verlaan, D.J., Laurent, S.B., Sure, U., Bertalanffy, H., Andermann, E., Andermann, F., Rouleau, G.A. and Siegel, A.M. (2004) CCM1 mutation screen of sporadic cases with cerebral cavernous malformations. Neurology, 62, 1213-1215.
29. Gault, J., Sain, S., Hu, L.J. and Awad, I.A. (2006) Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery, 59, 1278-1284. Discussion 1284-5.
30. Gaetzner, S., Stahl, S., Surucu, O., Schaafhausen, A., Halliger-Keller, B., Bertalanffy, H., Sure, U. and Felbor, U. (2007) CCM1 gene deletion identified by MLPA in cerebral cavernous malformation. Neurosurg. Rev., 30, 155-159.
31. Felbor, U., Gaetzner, S., Verlaan, D.J., Vijzelaar, R., Rouleau, G.A. and Siegel, A.M. (2007) Large germline deletions and duplication in isolated cerebral cavernous malformation patients. Neurogenetics, 8, 149-153.
32. Liquori, C.L., Berg, M.J., Squitieri, F., Leedom, T.P., Ptacek, L., Johnson, E.W. and Marchuk, D.A. (2007) Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am. J. Hum. Genet., 80, 69-75.
33. Denier, C., Labauge, P., Bergametti, F., Marchelli, F., Riant, F., Arnoult, M., Maciazek, J., Vicaut, E., Brunereau, L. and Tournier-Lasserve, E. (2006) Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann. Neurol., 60, 550-556.
34. Stahl, S., Gaetzner, S., Voss, K., Brackertz, B., Schleider, E., Surucu, O., Kunze, E., Netzer, C., Korenke, C., Finckh, U. et al. (2008) Novel CCM1, CCM2 and CCM3 mutations in patients with cerebral cavernous malformations: In-frame deletion in CCM2 prevents formation of a CCM1/ CCM2/CCM3 protein complex. Hum. Mutat., 29, 709-717.
35. Limaye, N., Wouters, V., Uebelhoer, M., Tuominen, M., Wirkkala, R., Mulliken, J.B., Eklund, L., Boon, L.M. and Vikkula, M. (2008) Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat. Genet., 41, 118-124.
36. Petit, N., Blecon, A., Denier, C. and Tournier-Lasserve, E. (2006) Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr. Patterns, 6, 495-503.
37. Hogan, B.M., Bussmann, J., Wolburg, H. and Schulte-Merker, S. (2008) ccm1 cell autonomously regulates endothelial cellular morphogenesis and vascular tubulogenesis in zebrafish. Hum. Mol. Genet., 17, 2424-2432.
38. Zawistowski, J.S., Stalheim, L., Uhlik, M.T., Abell, A.N., Ancrile, B.B., Johnson, G.L. and Marchuk, D.A. (2005) CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis. Hum. Mol. Genet., 14, 2521-2531.
39. Hilder, T.L., Malone, M.H., Bencharit, S., Colicelli, J., Haystead, T.A., Johnson, G.L. and Wu, C.C. (2007) Proteomic identification of the cerebral cavernous malformation signaling complex. J. Proteome Res. 6, 4343-4355.
40. Voss, K., Stahl, S., Schleider, E., Ullrich, S., Nickel, J., Mueller, T.D. and Felbor, U. (2007) CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics, 8, 249-256.
41. Zhang, J., Rigamonti, D., Dietz, H.C. and Clatterbuck, R.E. (2007) Interaction between krit1 and malcavernin: Implications for the pathogenesis of cerebral cavernous malformations. Neurosurgery, 60, 353-359. Discussion 359.
42. Uhlik, M.T., Abell, A.N., Johnson, N.L., Sun, W., Cuevas, B.D., Lobel-Rice, K.E., Horne, E.A., Dell'Acqua, M.L. and Johnson, G.L.' (2003) Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat. Cell Biol., 5, 1104-1110.
43. Serebriiskii, I., Estojak, J., Sonoda, G., Testa, J.R. and Golemis, E.A. (1997) Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene, 15, 1043-1049.
44. Zhang, J., Clatterbuck, R.E., Rigamonti, D., Chang, D.D. and Dietz, H.C. (2001) Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum. Mol. Genet., 10, 2953-2960.
45. Glading, A., Han, J., Stockton, R.A. and Ginsberg, M.H. (2007) KRIT-1/ CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J. Cell. Biol., 179, 247-254.
46. Gault, J., Shenkar, R., Recksiek, P. and Awad, I.A. (2005) Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke, 36, 872-874.
47. Akers, A.L., Johnson, E., Steinberg, G.K., Zabramski, J.M. and Marchuk, D.A. (2008) Biallelic somatic and germline mutations in cerebral cavernous malformations (CCM): Evidence for a two-hit mechanism of CCM pathogenesis. Hum. Mol. Genet., doi:10.1093/hmg/ddn430.
48. Pagenstecher, A., Stahl, S., Sure, U. and Felbor, U. (2008) A two-hit mechanism causes cerebral cavernous malformations: Complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum. Mol. Genet. doi:10.1093/hmg/ddn420.
49. Vikkula, M., Boon, L.M., Carraway, K.L. 3rd, Calvert, J.T., Diamonti, A.J., Goumnerov, B., Pasyk, K.A., Marchuk, D.A., Warman, M.L., Cantley, L.C. et al. (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell, 87, 1181-1190.
50. Boon, L.M., Mulliken, J.B., Enjolras, O. and Vikkula, M. (2004) Glomuvenous malformation (glomangioma) and venous malformation: Distinct clinicopathologic and genetic entities. Arch. Dermatol., 140 971-976.
51. Brouillard, P., Boon, L.M., Mulliken, J.B., Enjolras, O., Ghassibe, M., Warman, M.L., Tan, O.T., Olsen, B.R. and Vikkula, M. (2002) Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ('glomangiomas'). Am. J. Hum. Genet., 70, 866-874.
52. Brouillard, P., Ghassibe, M., Penington, A., Boon, L.M., Dompmartin, A., Temple, I.K., Cordisco, M., Adams, D., Piette, F., Harper, J.I. et al. (2005) Four common glomulin mutations cause two thirds of glomuvenous malformations ('familial glomangiomas'): Evidence for a founder effect. J. Med. Genet., 42, e13.
53. O'Hagan, A.H., Moloney, F.J., Buckley, C., Bingham, E.A., Walsh, M.Y., McKenna, K.E., McGibbon, D. and Hughes, A.E. (2006) Mutation analysis in Irish families with glomuvenous malformations. Br. J. Dermatol., 154, 450-452.
54. Brouillard, P., Enjolras, O., Boon, L.M. and Vikkula, M. (2008) Glomulin and glomuvenous malformation. Epstein, C.J., Erickson, R.P. and Wynshaw-Boris, A. (eds), Inborn Errors of Development. Oxford University Press, New York, pp. 1561-1565.
55. Boon, L.M. and Vikkula, M. From blue jeans to blue genes. J. Craniofac. Surg. In press.
56. Calvert, J.T., Riney, T.J., Kontos, C.D., Cha, E.H., Prieto, V.G., Shea, C.R., Berg, J.N., Nevin, N.C., Simpson, S.A., Pasyk, K.A. et al. (1999) Allelic and locus heterogeneity in inherited venous malformations. Hum. Mol. Genet., 8, 1279-1289.
57. Morris, P.N., Dunmore, B.J., Tadros, A., Marchuk, D.A., Darland, D.C., D'Amore, P.A. and Brindle, N.P. (2005) Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations. J. Mol. Med., 83, 58-63.
58. Hu, H.T., Huang, Y.H., Chang, Y.A., Lee, C.K., Jiang, M.J. and Wu, L.W. (2008) Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression. J. Invest. Dermatol. 128, 2325-2333.
59. Korpelainen, E.I., Karkkainen, M., Gunji, Y., Vikkula, M. and Alitalo, K. (1999) Endothelial receptor tyrosine kinases activate the STAT signaling pathway: Mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene, 18, 1-8.
60. Kidoya, H., Ueno, M., Yamada, Y., Mochizuki, N., Nakata, M., Yano, T., Fujii, R. and Takakura, N. (2008) Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J., 27, 522-534.
61. Wouters, V., Boon, L.M., Mulliken, J.B. and Vikkula, M. (2008) TEK (TIE2) and cutaneomucosal venous malformation. In Epstein, C.J., Erickson, R.P. and Wynshaw-Boris, A. (eds.), Inborn Errors of Development. 2nd edn. Oxford University Press, Oxford. pp. 491-494.
62. Dompmartin, A., Acher, A., Thibon, P., Tourbach, S., Hermans, C., Deneys, V., Pocock, B., Lequerrec, A., Labbe, D., Barrellier, M.T. et al. (2008) Association of localized intravascular coagulopathy with venous malformations. Arch. Dermatol., 144, 873-877.
63. Fukuhara, S., Sako, K., Minami, T., Noda, K., Kim, H.Z., Kodama, T., Shibuya, M., Takakura, N., Koh, G.Y. and Mochizuki, N. (2008) Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol., 10, 513-526.
64. Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G.Y. et al. (2008) Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell. Biol., 10, 527-537.
65. Saharinen, P., Kerkela, K., Ekman, N., Marron, M., Brindle, N., Lee, G.M., Augustin, H., Koh, G.Y. and Alitalo, K. (2005) Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J. Cell. Biol., 169, 239-243.
66. Yuan, H.T., Venkatesha, S., Chan, B., Deutsch, U., Mammoto, T., Sukhatme, V.P., Woolf, A.S. and Karumanchi, S.A. (2007) Activation of the orphan endothelial receptor Tiel modifies Tie2-mediated intracellular signaling and cell survival. FASEB J., 21, 3171-3183.
67. Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N. et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60.
68. Valenzuela, D.M., Griffiths, J.A., Rojas, J., Aldrich, T.H., Jones, P.F., Zhou, H., McClain, J., Copeland, N.G., Gilbert, D.J., Jenkins, N.A. et al. (1999) Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc. Natl Acad. Sci. USA, 96 1904-1909.
69. Loughna, S. and Sato, T.N. (2001) Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol., 20, 319-325.
70. Cascone, I., Napione, L., Maniero, F., Serini, G. and Bussolino, F. (2005) Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J. Cell. Biol., 170, 993-1004.
71. Kim, K.L., Shin, I.S., Kim, J.M., Choi, J.H., Byun, J., Jeon, E.S., Suh, W. and Kim, D.K. (2006) Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc. Res., 72, 394-402.
72. Fachinger, G., Deutsch, U. and Risau, W. (1999) Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene, 18, 5948-5953.
73. Dominguez, M.G., Hughes, V.C., Pan, L., Simmons, M., Daly, C., Anderson, K., Noguera-Troise, I., Murphy, A.J., Valenzuela, D.M., Davis, S. et al. (2007) Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc. Natl Acad. Sci. USA, 104, 3243-3248.
74. Irrthum, A., Karkkainen, M.J., Devriendt, K., Alitalo, K. and Vikkula, M. (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am. J. Hum. Genet., 67, 295-301.
75. Karkkainen, M.J., Ferrell, R.E., Lawrence, E.C., Kimak, M.A., Levinson, K.L., McTigue, M.A., Alitalo, K. and Finegold, D.N. (2000) Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet., 25, 153-159.
76. Evans, A.L., Bell, R., Brice, G., Comeglio, P., Lipede, C., Jeffery, S., Mortimer, P., Sarfarazi, M. and Child, A.H. (2003) Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J. Med. Genet., 40, 697-703.
77. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N. and Alitalo, K. (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15, 290-298.
78. Achen, M.G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A.F., Alitalo, K. and Stacker, S.A. (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA, 95, 548-553.
79. Brice, G., Child, A.H., Evans, A., Bell, R., Mansour, S., Burnand, K., Sarfarazi, M., Jeffery, S. and Mortimer, P. (2005) Milroy disease and the VEGFR-3 mutation phenotype. J. Med. Genet., 42, 98-102.
80. Daniel-Spiegel, E., Ghalamkarpour, A., Spiegel, R., Weiner, E., Vikkula, M., Shalev, E. and Shalev, S.A. (2005) Hydrops fetalis: An unusual prenatal presentation of hereditary congenital lymphedema. Prenat. Diagn., 25, 1015-1018.
81. Ghalamkarpour, A., Morlot, S., Raas-Rothschild, A., Utkus, A., Mulliken, J.B., Boon, L.M. and Vikkula, M. (2006) Hereditary lymphedema type I associated with VEGFR3 mutation: The first de novo case and atypical presentations. Clin. Genet., 70, 330-335.
82. Carver, C., Brice, G., Mansour, S., Ostergaard, P., Mortimer, P. and Jeffery, S. (2007) Three children with Milroy disease and de novo mutations in VEGFR3. Clin. Genet., 71, 187-189.
83. Ghalamkarpour, A., Debauche, C., Haan, E., Van Regemorter, N., Sznajer, Y., Thomas, D., Revencu, N., Gillerot, Y., Boon, L.M. and Vikkula, M. (Submitted) Sporadic hydrops fetalis caused by mutations in lymphangiogenic factors VEGFR3 and FOXC2. J. Pediatr. In press.
84. Ghalamkarpour, A., Holnthoner, W., Saharinen, P., Boon, L.M., Mulliken, J.B., Alitalo, K. and Vikkula, M. (Submitted) Primary Human Molecular Genetics, 2009, Vol. 18, Review Issue 1 73 Congenital Lymphedema can be caused by a recessive VEGFR3 mutation. J. Med. Genet. In press.
85. Malik, S. and Grzeschik, K.H. (2008) Congenital, low penetrance lymphedema of lower limbs maps to chromosome 6q16.2-q22.1 in an inbred Pakistani family. Hum. Genet., 123, 197-205.
86. Ferrell, R.E., Kimak, M.A., Lawrence, E.C. and Finegold, D.N. (2008) Candidate gene analysis in primary lymphedema. Lymphat. Res. Biol. 6, 69-76.
87. Finegold, D.N., Schacht, V., Kimak, M.A., Lawrence, E.C., Foeldi, E., Karlsson, J.M., Baty, C.J. and Ferrell, R.E. (2008) HGF and MET mutations in primary and secondary lymphedema. Lymphat. Res. Biol. 6, 65-68.
88. Fang, J., Dagenais, S.L., Erickson, R.P., Arlt, M.F., Glynn, M.W., Gorski, J.L., Seaver, L.H. and Glover, T.W. (2000) Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet., 67, 1382-1388.
89. Bell, R., Brice, G., Child, A.H., Murday, V.A., Mansour, S., Sandy, C.J., Collin, J.R., Brady, A.F., Callen, D.F., Burnand, K. et al. (2001) Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum. Genet., 108, 546-551.
90. Finegold, D.N., Kimak, M.A., Lawrence, E.C., Levinson, K.L., Cherniske, E.M., Pober, B.R., Dunlap, J.W. and Ferrell, R.E. (2001) Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum. Mol. Genet., 10, 1185-1189.
91. Xue, Y., Cao, R., Nilsson, D., Chen, S., Westergren, R., Hedlund, E.M., Martijn, C., Rondahl, L., Krauli, P., Walum, E. et al. (2008) FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc. Natl Acad. Sci. USA, 105, 10167-10172.
92. Hayashi, H., Sano, H., Seo, S. and Kume, T. (2008) The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J. Biol. Chem., 283, 23791-23800.
93. Hayashi, H. and Kume, T. (2008) Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS ONE, 3, e2401.
94. Petrova, T.V., Karpanen, T., Norrmen, C., Mellor, R., Tamakoshi, T., Finegold, D., Ferrell, R., Kerjaschki, D., Mortimer, P., Yla-Herttuala, S. et al. (2004) Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat. Med., 10, 974-981.
95. Irrthum, A., Devriendt, K., Chitayat, D., Matthijs, G., Glade, C., Steijlen, P.M., Fryns, J.P., Van Steensel, M.A. and Vikkula, M. (2003) Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am. J. Hum. Genet., 72, 1470-1478.
96. Francois, M., Caprini, A., Hosking, B., Orsenigo, F., Wilhelm, D., Browne, C., Paavonen, K., Karnezis, T., Shayan, R., Downes, M. et al. (2008) Sox18 induces development of the lymphatic vasculature in mice. Nature, 456, 643-647.
97. Ghalamkarpour, A., Devriendt, K. and Vikkula, M. (2008) SOX18 and the Hypotrichosis-Lymphedema-Telangiectasia Syndrome. In Epstein, C.J., Erickson, R.P. and Wynshaw-Boris, A. (eds.), Inborn Errors of Development. 2nd edn. Oxford University Press, Oxford. pp. 913-915.
98. Cermenati, S., Moleri, S., Cimbro, S., Corti, P., Del Giacco, L., Amodeo, R., Dejana, E., Koopman, P., Cotelli, F. and Beltrame, M. (2008) Sox18 and Sox7 play redundant roles in vascular development. Blood 111, 2657-2666.
99. Herpers, R., van de Kamp, E., Duckers, H.J. and Schulte-Merker, S. (2008) Redundant roles for sox7 and sox18 in arteriovenous specification in zebrafish. Circ. Res., 102, 12-15.
100. Pendeville, H., Winandy, M., Manfroid, I., Nivelles, O., Motte, P., Pasque, V., Peers, B., Struman, I., Martial, J.A. and Voz, M.L. (2008) Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Dev. Biol., 317, 405-416.
101. Plummer, N.W., Gallione, C.J., Srinivasan, S., Zawistowski, J.S., Louis, D.N. and Marchuk, D.A. (2004) Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am. J. Pathol., 165, 1509-1518.
102. Plummer, N.W., Squire, T.L., Srinivasan, S., Huang, E., Zawistowski, J.S., Matsunami, H., Hale, L.P. and Marchuk, D.A. (2006) Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm. Genome, 17, 119-128.
103. Eklund, L. and Olsen, B.R. (2006) Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp. Cell Res., 312, 630-641.
104. Karpanen, T. and Alitalo, K. (2008) Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol., 3, 367-397.
105. Karkkainen, M.J., Saaristo, A., Jussila, L., Karila, K.A., Lawrence, E.C., Pajusola, K., Bueler, H., Eichmann, A., Kauppinen, R., Kettunen, M.I. et al. (2001) A model for gene therapy of human hereditary lymphedema. Proc. Natl Acad. Sci. USA, 98, 12677-12682.
106. Pennisi, D., Gardner, J., Chambers, D., Hosking, B., Peters, J., Muscat, G., Abbott, C. and Koopman, P. (2000) Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat. Genet. 24, 434-437.
107. James, K., Hosking, B., Gardner, J., Muscat, G.E. and Koopman, P. (2003) Sox18 mutations in the ragged mouse alleles ragged-like and opossum. Genesis, 36, 1-6.
108. Bull, L.N., Roche, E., Song, E.J., Pedersen, J., Knisely, A.S., van Der Hagen, C.B., Eiklid, K., Aagenaes, O. and Freimer, N.B. (2000) Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am. J. Hum. Genet., 67, 994-999.
109. McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrell, J. et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 8, 345-351.
110. Johnson, D.W., Berg, J.N., Baldwin, M.A., Gallione, C.J., Marondel, I., Yoon, S.J., Stenzel, T.T., Speer, M., Pericak-Vance, M.A., Diamond, A. et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet., 13, 189-195.
111. Bourdeau, A., Faughnan, M.E. and Letarte, M. (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc. Med., 10, 279-285.
112. Srinivasan, S., Hanes, M.A., Dickens, T., Porteous, M.E., Oh, S.P., Hale, L.P. and Marchuk, D.A. (2003) A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet., 12 473-482.
113. Cole, S.G., Begbie, M.E., Wallace, G.M. and Shovlin, C.L. (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J. Med. Genet., 42, 577-582.
114. Bayrak-Toydemir, P., McDonald, J., Akarsu, N., Toydemir, R.M., Calderon, F., Tuncali, T., Tang, W., Miller, F. and Mao, R. (2006) A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am. J. Med. Genet. A, 140, 2155-2162.
115. Abdalla, S.A. and Letarte, M. (2006) Hereditary haemorrhagic telangiectasia: Current views on genetics and mechanisms of disease. J. Med. Genet., 43, 97-110.
116. Xu, X., Brodie, S.G., Yang, X., Im, Y.H., Parks, W.T., Chen, L., Zhou, Y.X., Weinstein, M., Kim, S.J. and Deng, C.X. (2000) Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene, 19, 1868-1874.
117. Gallione, C.J., Repetto, G.M., Legius, E., Rustgi, A.K., Schelley, S.L., Tejpar, S., Mitchell, G., Drouin, E., Westermann, C.J. and Marchuk, D.A. (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet, 363, 852-859.